IRCT201206304412N6已完成2 期
Randomized double blind clinical trial (phase 2) RAZI- MMR vaccines in comparison with a standard vaccine in 12 – 24 months old children.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 420
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 1 year 至 2 years（—）
- 性别
- All
入选标准
- •in 12 – 24 months old children
- •Negative history of any exposure to measeles , rubella and mumps in the the preceding 4 weeks ; Negative history of previous MMR immunization ; Negative history of immunosuppressive therapy; Negative history of previous infection by measeles , rubella and mumps viruses ; obtaining written informed consent ; Negative history of radiotherapy;
- •Exclusion criteria : in 12 – 24 months old children
- •Positive history of autoimmune disorders , genetic and congenital disease; Positive history of kidney and liver disease; fever of >38.cc at time of assessment; Positive history of other signs of acute infections; Positive history of administration immunoglobins or blood transfusions within the previous three months; Positive history of allergy to any vaccine components; Positive history of prematurity ,mental retardation ; Positive history of convulsion or any neurological disorder;
排除标准
- 未提供
研究者
相似试验
尚未招募
2 期
INFINiTE-CV2 Phase IIa Trial: INterFeron type 1 Intra-Nasal gel Therapy for Early treatment of SARS-CoV2 (COVID-19)ACTRN12622000258752IntraVital100
招募中
2 期
Phase 2 study of oral semaglutide tablet for patients with Parkinson's diseaseD010300Parkinson's diseaseJPRN-jRCT2051230090Kimura Yasuyoshi99
进行中（未招募）
2 期
Sotagliflozin in patients with heart failure symptoms and type 1 diabetesType 1 Diabetes, Heart FailureNutritional, Metabolic, EndocrineISRCTN79322795niversity of Dundee320
进行中（未招募）
不适用
(REASON) double-blind, Randomized phase II study to Evaluate the safety and efficacy of Acetyl-l-carnitine in the prevention of SagOpilone-induced peripheral Neuropathy. - REASOEUCTR2008-000879-26-BEBayer Schering Pharma AG140
进行中（未招募）
1 期
(REASON) double-blind, Randomized phase II study to Evaluate the safety and efficacy of Acetyl-l-carnitine in the prevention of SagOpilone-induced peripheral Neuropathy. - REASOEUCTR2008-000879-26-FRBayer Schering Pharma AG